SCHEMBL23515802

SCHEMBL23515802

c1ccc(-c2ccc(N(c3ccc4c(c3)sc3ccccc34)c3ccc4sc5cc(N(c6ccccc6)c6ccc7c(c6)sc6ccc(N(c8ccccc8)c8ccccc8)cc67)ccc5c4c3)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GPR3 P46089 1/20 0.41
CYP1A2 P05177 2/20 0.37
LIMK1 P53667 2/20 0.35
PTPN7 P35236 1/20 0.35
DUSP3 P51452 1/20 0.35
PTPN12 Q05209 1/20 0.35
PTPN22 Q9Y2R2 1/20 0.35
TDP1 Q9NUW8 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
APP P05067 1/20 0.35
TNKS O95271 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
POLB P06746 1/20 0.35
PIM3 Q86V86 1/20 0.35
PTGIR P43119 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19239067 1.00 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL19239069 1.00 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL21281805 1.00 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL21966043 1.00 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL21966368 1.00 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL21966472 1.00 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL21966047 1.00 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL21966370 1.00 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL21128582 1.00 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL18927738 1.00 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230157160-A1 COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE DUK SAN NEOLUX CO., LTD. (KR) 2023-05-18 US disclosed
US-20230157160-A1 COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE DUK SAN NEOLUX CO., LTD. (KR) 2023-05-18 US disclosed
US-20230009845-A1 ORGANIC ELECTRIC ELEMENT COMPRISING A PLURALITY OF EMISSION-AUXILIARY LAYERS AND ELECTRONIC DEVICE COMPRISING IT DUK SAN NEOLUX CO., LTD. (KR) 2023-01-12 US disclosed
US-11552253-B2 Compound for organic electric device, organic electric device using same, and electronic device DUK SAN NEOLUX CO., LTD. (KR) 2023-01-10 US disclosed
US-20210184129-A1 COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME AND ELECTRONIC DEVICE THEREOF DUK SAN NEOLUX CO., LTD (KR) 2021-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11552253-B2 Compound for organic electric device, organic electric device using same, and electronic device OR10J3, OR51E2, ORAI2 MAPT 1777/4885ALDH1A1 999/4885HPGD 1996/4885
US-20210184129-A1 COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME AND ELECTRONIC DEVICE THEREOF OR51E2, SLC39A11, WEE1 MAPT 1639/4885ALDH1A1 2143/4885HPGD 3084/4885
US-20230157160-A1 COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE OR10J3, OR51E2, ORAI2 MAPT 1758/4885ALDH1A1 1082/4885HPGD 2154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.